Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.

Literature DB >> 6315595

The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.

G Seibert, M Limbert, I Winkler, T Dick.

Abstract

The antibacterial activity of the cephalosporin antibiotic HR 810 was evaluated in comparison with cefoperazone, cefotaxime, ceftazidime, ceftriaxone, latamoxef, gentamicin and amikacin against 1500 clinical isolates. HR 810 is the antibiotic with the broadest antimicrobial spectrum. It is also highly active against isolates of the genera Pseudomonas, Enterobacter, Staphylococcus and enterococci. HR 810 is very stable against hydrolysis by plasmid-coded and chromosomally coded beta-lactamases.

Entities: Chemical

Mesh：

Substances：

Year: 1983 PMID： 6315595 DOI： 10.1007/bf01641262

Source DB: PubMed Journal: Infection ISSN： 0300-8126 Impact factor: 3.553

4 in total

Review 1. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.

Authors: H C Neu
Journal: Annu Rev Pharmacol Toxicol Date: 1982 Impact factor: 13.820

2. Comparative activities of 13 beta-lactam antibiotics.

Authors: H L Muytjens; J van der Ros-van de Repe
Journal: Antimicrob Agents Chemother Date: 1982-06 Impact factor: 5.191

3. Sensitivity of gram-negative bacteria to six aminoglycoside antibiotics.

Authors: L Eyckmans; J Beert
Journal: Infection Date: 1977 Impact factor: 3.553

4. HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum.

Authors: G Seibert; N Klesel; M Limbert; E Schrinner; K Seeger; I Winkler; R Lattrell; J Blumbach; W Dürckheimer; K Fleischmann
Journal: Arzneimittelforschung Date: 1983

4 in total

21 in total

1. Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.

Authors: S Arai; S Hayashi
Journal: Infection Date: 1990 May-Jun Impact factor: 3.553

2. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

Authors: A Bauernfeind; S Schweighart; E Eberlein; R Jungwirth
Journal: Infection Date: 1991 Impact factor: 3.553

3. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers.

Authors: L Maass; V Malerczyk; M Verho
Journal: Infection Date: 1987 May-Jun Impact factor: 3.553

4. Microanalytical high-performance liquid chromatography assay for cefpirome (HR 810) in serum.

Authors: C P Turley; G L Kearns; R F Jacobs
Journal: Antimicrob Agents Chemother Date: 1988-10 Impact factor: 5.191

5. Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

Authors: P A Bradford; C C Sanders
Journal: Antimicrob Agents Chemother Date: 1995-02 Impact factor: 5.191

The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.

Review 1. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.

2. Comparative activities of 13 beta-lactam antibiotics.

3. Sensitivity of gram-negative bacteria to six aminoglycoside antibiotics.

4. HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum.

1. Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.

2. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

3. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers.

4. Microanalytical high-performance liquid chromatography assay for cefpirome (HR 810) in serum.

5. Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

6. Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals.

7. Antimicrobial activity of HR810 against 419 strict anaerobic bacteria.

8. In vitro activity of HR 810, a new cephalosporin.

9. Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.

10. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.